Haven't used Promedior yet?

Ask AI about Promedior

Quick answers generated from reviews and public information about this company.

AI-generated answers may be inaccurate. Check important details with the company directly.

Adam Oestergaard
Reviews 1

I recently had a medical procedure done and the experience was amazing. The staff at Promedior was very professional and made me feel comfortable throughout the process. I would highly recommend their services to anyone in need.

Fredek Robok
Reviews 1

I recently used Promedior for my medical needs and I must say I had an average experience. The customer service was good and the staff was friendly. However, I found the prices to be a bit high compared to other medical facilities in the area. Overall, it was an okay experience.

Questions & Answers

No questions yet — be the first to ask.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website — its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="promedior-com" data-lang="en"></div>
More widgets

About Promedior

Promedior is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases Promedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By specifically targeting these cells at the site of injury, Promedior is able to treat the source of aberrant immune system responses, promote tissue healing and resolution, and greatly reduce the risk of systemic side effects inherent in current therapeutic approaches. Promedior is developing drugs to address the most severe and difficult-to-treat fibrotic and inflammatory conditions of the eye, lung and kidney such as glaucoma, age-related macular degeneration, diabetic retinopathy and dry eye disease; pulmonary fibrosis, scleroderma and COPD; and acute and chronic nephropathy.